Noerr advised Catalio Capital Management LP on the deal. ATAI Life Sciences, a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, announced...
Noerr advised Catalio Capital Management LP on the deal. ATAI Life Sciences, a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, announced...